Chongqing Pharscin Pharmaceutical Co Ltd (002907) - Net Assets
Based on the latest financial reports, Chongqing Pharscin Pharmaceutical Co Ltd (002907) has net assets worth CN¥1.71 Billion CNY (≈ $250.23 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥2.00 Billion ≈ $292.33 Million USD) and total liabilities (CN¥287.66 Million ≈ $42.09 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 002907 PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.71 Billion |
| % of Total Assets | 85.6% |
| Annual Growth Rate | 19.18% |
| 5-Year Change | 40.46% |
| 10-Year Change | 353.91% |
| Growth Volatility | 14.96 |
Chongqing Pharscin Pharmaceutical Co Ltd - Net Assets Trend (2013–2024)
This chart illustrates how Chongqing Pharscin Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see Chongqing Pharscin Pharmaceutical Co Ltd (002907) market capitalisation.
Annual Net Assets for Chongqing Pharscin Pharmaceutical Co Ltd (2013–2024)
The table below shows the annual net assets of Chongqing Pharscin Pharmaceutical Co Ltd from 2013 to 2024. Also explore how fast is Chongqing Pharscin Pharmaceutical Co Ltd growing its equity to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.66 Billion ≈ $242.91 Million |
+2.60% |
| 2023-12-31 | CN¥1.62 Billion ≈ $236.75 Million |
+0.47% |
| 2022-12-31 | CN¥1.61 Billion ≈ $235.65 Million |
+27.21% |
| 2021-12-31 | CN¥1.27 Billion ≈ $185.24 Million |
+7.12% |
| 2020-12-31 | CN¥1.18 Billion ≈ $172.94 Million |
+10.37% |
| 2019-12-31 | CN¥1.07 Billion ≈ $156.69 Million |
+29.18% |
| 2018-12-31 | CN¥828.91 Million ≈ $121.30 Million |
+15.14% |
| 2017-12-31 | CN¥719.95 Million ≈ $105.35 Million |
+56.03% |
| 2016-12-31 | CN¥461.42 Million ≈ $67.52 Million |
+26.17% |
| 2015-12-31 | CN¥365.71 Million ≈ $53.51 Million |
+22.00% |
| 2014-12-31 | CN¥299.77 Million ≈ $43.87 Million |
+24.40% |
| 2013-12-31 | CN¥240.97 Million ≈ $35.26 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Chongqing Pharscin Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 384.8% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥681.63 Million | 41.06% |
| Common Stock | CN¥417.60 Million | 25.16% |
| Other Components | CN¥560.77 Million | 33.78% |
| Total Equity | CN¥1.66 Billion | 100.00% |
Chongqing Pharscin Pharmaceutical Co Ltd Competitors by Market Cap
The table below lists competitors of Chongqing Pharscin Pharmaceutical Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Shenzhen Tianyuan Dic Info Tech
SHE:300047
|
$847.36 Million |
|
Core Lithium Ltd
AU:CXO
|
$847.39 Million |
|
TrustCo Bank Corp NY
NASDAQ:TRST
|
$847.70 Million |
|
Sinoseal Holding Co Ltd
SHE:300470
|
$847.71 Million |
|
Flowco Holdings Inc.
NYSE:FLOC
|
$846.94 Million |
|
Nesco Limited
NSE:NESCO
|
$846.81 Million |
|
Shenzhen Tellus Holding Co Ltd
SHE:000025
|
$846.62 Million |
|
Darma Henwa Tbk
JK:DEWA
|
$846.60 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Chongqing Pharscin Pharmaceutical Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,617,921,000 to 1,659,998,000, a change of 42,077,000 (2.6%).
- Net income of 76,730,000 contributed positively to equity growth.
- Dividend payments of 35,496,000 reduced retained earnings.
- Other comprehensive income decreased equity by 101,576,000.
- Other factors increased equity by 102,419,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥76.73 Million | +4.62% |
| Dividends Paid | CN¥35.50 Million | -2.14% |
| Other Comprehensive Income | CN¥-101.58 Million | -6.12% |
| Other Changes | CN¥102.42 Million | +6.17% |
| Total Change | CN¥- | 2.60% |
Book Value vs Market Value Analysis
This analysis compares Chongqing Pharscin Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.49x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 21.39x to 3.49x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | CN¥0.65 | CN¥13.86 | x |
| 2014-12-31 | CN¥0.73 | CN¥13.86 | x |
| 2015-12-31 | CN¥1.02 | CN¥13.86 | x |
| 2016-12-31 | CN¥1.28 | CN¥13.86 | x |
| 2017-12-31 | CN¥1.96 | CN¥13.86 | x |
| 2018-12-31 | CN¥2.07 | CN¥13.86 | x |
| 2019-12-31 | CN¥2.68 | CN¥13.86 | x |
| 2020-12-31 | CN¥2.95 | CN¥13.86 | x |
| 2021-12-31 | CN¥3.16 | CN¥13.86 | x |
| 2022-12-31 | CN¥3.99 | CN¥13.86 | x |
| 2023-12-31 | CN¥3.87 | CN¥13.86 | x |
| 2024-12-31 | CN¥3.97 | CN¥13.86 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Chongqing Pharscin Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 4.62%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 9.90%
- • Asset Turnover: 0.40x
- • Equity Multiplier: 1.16x
- Recent ROE (4.62%) is below the historical average (12.63%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 12.41% | 8.33% | 0.84x | 1.78x | CN¥5.61 Million |
| 2014 | 20.12% | 13.80% | 0.79x | 1.84x | CN¥29.55 Million |
| 2015 | 20.19% | 15.73% | 0.87x | 1.47x | CN¥37.27 Million |
| 2016 | 20.74% | 17.35% | 0.85x | 1.41x | CN¥49.57 Million |
| 2017 | 15.55% | 18.91% | 0.67x | 1.23x | CN¥39.99 Million |
| 2018 | 16.57% | 19.53% | 0.64x | 1.32x | CN¥54.48 Million |
| 2019 | 15.85% | 20.16% | 0.51x | 1.53x | CN¥62.67 Million |
| 2020 | 10.09% | 13.51% | 0.51x | 1.46x | CN¥1.00 Million |
| 2021 | 7.25% | 10.85% | 0.48x | 1.40x | CN¥-34.81 Million |
| 2022 | 6.11% | 12.53% | 0.42x | 1.16x | CN¥-62.64 Million |
| 2023 | 2.02% | 4.73% | 0.37x | 1.14x | CN¥-129.09 Million |
| 2024 | 4.62% | 9.90% | 0.40x | 1.16x | CN¥-89.27 Million |
Industry Comparison
This section compares Chongqing Pharscin Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $8,448,219,723
- Average return on equity (ROE) among peers: 10.70%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Chongqing Pharscin Pharmaceutical Co Ltd (002907) | CN¥1.71 Billion | 12.41% | 0.17x | $846.95 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $2.14 Billion | 22.15% | 4.96x | $585.22 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $1.15 Billion | 3.98% | 1.16x | $407.31 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $897.61 Million | 10.79% | 0.14x | $4.27 Billion |
| Livzon Pharmaceutical Group Inc (000513) | $14.94 Billion | 12.78% | 0.66x | $2.26 Billion |
| Wedge Industrial Co Ltd (000534) | $552.92 Million | 0.39% | 0.01x | $1.78 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $38.10 Billion | 10.98% | 0.30x | $13.33 Billion |
| Hainan Haiyao Co Ltd (000566) | $5.63 Billion | 2.92% | 0.71x | $875.19 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $141.91 Million | 11.01% | 0.32x | $311.17 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $2.05 Billion | 23.18% | 1.96x | $973.03 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $18.87 Billion | 8.83% | 0.08x | $3.07 Billion |
About Chongqing Pharscin Pharmaceutical Co Ltd
Chongqing Pharscin Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of drugs in China. The company offers tablets, powders, granules, soft capsules, powder injections, freeze-dried powders, injections, chemical raw materials, and small volume injections. It provides its products for the treatment of CNS, digestion, otolaryngology, oncology, cardiovascular, an… Read more